retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 Retatrutide, a GIP, and receptor agonist, for people with type diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, 2 trial conducted in the USA 𝗧𝗵𝗲 𝗘𝗳𝗳𝗲𝗰𝘁 𝗼𝗳 𝗚𝗟𝗣-𝟭 𝗥𝗲𝗰𝗲𝗽𝘁𝗼𝗿

OCP adjustment: for patients who must use oral contraceptive pills (OCPs) for cycle regulation, the risk of reduced efficacy must be clearly communicated if using tirzepatide

If your TSH is abnormal, your provider may order additional thyroid tests (free T4, free T3) before proceeding

GLP-1 Insight 21 Family oriented packaged foods hold strong even as other categories change

The Patient Medication Guide was updated to warn of the risk of severe stomach problems

A retrospective longitudinal analysis of ambulatory care data with a median follow-up of 3.5 years showed that twice-daily exenatide use with or without insulin was associated with significantly fewer cardiovascular events than insulin treatment [101]